Announced details
Long-term storage of anticancer drugs, continued administration, commercialization, and a Phase 3 clinical trial for combination therapy with DFP-10917 and Venetoclax
The conventional formulation had stability of approximately 3 months at around room temperature. The new formulation’s long-term stability of more than 5 years was confirmed at industrial scale.
The Company developed the formulation technology for DFP-10917, filed an international application with WIPO, and had it published internationally. Going forward, the Company plans to discuss with the FDA a request for conditional NDA approval and the transition to a Phase 3 clinical trial.
The International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the body responsible for international publication. The U.S. Food and Drug Administration (FDA) is the U.S. regulatory authority for pharmaceuticals. Other details: Not disclosed.
An international application was filed under the Patent Cooperation Treaty (PCT) and published internationally by WIPO’s International Bureau (IB). Registration number and validity period: Not disclosed.
Industrial scale
The Company says it will use the formulation technology under the present invention in the development and commercialization of DFP-10917 and link this to future business expansion, but the specific amount of the impact on financial results is Not disclosed.
The company does not address Contract Value / Offering price.
World Intellectual Property Organization (WIPO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | DFP-10917, Combination therapy of DFP-10917 and venetoclax |
| Counterparty | World Intellectual Property Organization (WIPO), U.S. Food and Drug Administration (FDA) |
| Counterparty overview | The International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the body responsible for international publication. The U.S. Food and Drug Administration (FDA) is the U.S. regulatory authority for pharmaceuticals. Other details: Not disclosed. |
| Relationship with the Company | The Company developed the formulation technology for DFP-10917, filed an international application with WIPO, and had it published internationally. Going forward, the Company plans to discuss with the FDA a request for conditional NDA approval and the transition to a Phase 3 clinical trial. |
| Applicable area | Long-term storage of anticancer drugs, continued administration, commercialization, and a Phase 3 clinical trial for combination therapy with DFP-10917 and Venetoclax |
| Registration number and expiry date | An international application was filed under the Patent Cooperation Treaty (PCT) and published internationally by WIPO’s International Bureau (IB). Registration number and validity period: Not disclosed. |
| Location scale | Industrial scale |
| Quantitative Effects | The conventional formulation had stability of approximately 3 months at around room temperature. The new formulation’s long-term stability of more than 5 years was confirmed at industrial scale. |
| Impact on Business Performance | The Company says it will use the formulation technology under the present invention in the development and commercialization of DFP-10917 and link this to future business expansion, but the specific amount of the impact on financial results is Not disclosed. |
| Source | World Intellectual Property Organization (WIPO) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The conventional lyophilized formulation had stability of only approximately 3 months at around room temperature, creating challenges for commercialization intended for long-term storage and continued administration. The new technology promotes the growth of Type II microcrystals in DFP-10917, achieving long-term stability.